Outcome of transplantation
| . | Study group . | Control group . |
|---|---|---|
| Engraftment | ||
| Time to ANC more than 0.5 × 109/L (days) | 11 (9-20) | 20 (14-28) |
| Primary engraftment | 26 (84%) | 26 (100%) |
| Secondary engraftment (after immune reconditioning + 2nd CD34+ infusion) | 5 (16%) | 0 |
| GVHD | ||
| Primary acute GVHD* | ||
| Grade 0 | 23 | 1 |
| Grade I | 4 | 5 |
| Grade II | 1 | 12 |
| Grades III-IV | 2 | 8 |
| Secondary acute GVHD (after donor T-cell infusion) | ||
| Grade II | 1 | NA |
| Grades III-IV | 2 | NA |
| Chronic (% of evaluable patients) | 2/27 (7%), lim | 9/22 (41%), lim + ext |
| Cause of death | ||
| Relapse | 8 | 8 |
| Infection | ||
| Viral | 5 | NK |
| Fungal | 2 | 2 |
| Bacterial | 1 | 1 |
| Unknown origin | 2 | 1 |
| GVHD | 1 | 7 |
| . | Study group . | Control group . |
|---|---|---|
| Engraftment | ||
| Time to ANC more than 0.5 × 109/L (days) | 11 (9-20) | 20 (14-28) |
| Primary engraftment | 26 (84%) | 26 (100%) |
| Secondary engraftment (after immune reconditioning + 2nd CD34+ infusion) | 5 (16%) | 0 |
| GVHD | ||
| Primary acute GVHD* | ||
| Grade 0 | 23 | 1 |
| Grade I | 4 | 5 |
| Grade II | 1 | 12 |
| Grades III-IV | 2 | 8 |
| Secondary acute GVHD (after donor T-cell infusion) | ||
| Grade II | 1 | NA |
| Grades III-IV | 2 | NA |
| Chronic (% of evaluable patients) | 2/27 (7%), lim | 9/22 (41%), lim + ext |
| Cause of death | ||
| Relapse | 8 | 8 |
| Infection | ||
| Viral | 5 | NK |
| Fungal | 2 | 2 |
| Bacterial | 1 | 1 |
| Unknown origin | 2 | 1 |
| GVHD | 1 | 7 |
NA indicates not applicable; NK, not known; lim, limited; and ext, extensive.
For evaluation of primary acute GVHD, 30 patients were considered; one patient who had received a donor T-cell infusion on day 0 was excluded.